RSS
24 Feb 2023

Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients

Author: admintech | Filed under: Press Release

Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in Europe The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies PARIS, Feb. 24, 2023 /PRNewswire/ — Servier, a global pharmaceutical company, today…

This entry was posted on Friday, February 24th, 2023 at 7:12 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»